Loading...
•
Jun 30, 2020
Nkarta Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020.
Key Takeaways
Nkarta reported financial results for Q2 2020, highlighting the completion of their IPO raising $289.8 million and progress in their NK cell therapy development.
Co-Lead programs on track with NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021.
Completed construction of cGMP clinical manufacturing facility.
Completed initial public offering of common stock on July 14, 2020, raising $289.8 million in gross proceeds.
Cash and cash equivalents of $341.8 million (pro forma) as of June 30, 2020, believed to be sufficient to fund operations into at least the second half of 2023
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023. The company expects cash and cash equivalents at December 31, 2020 to be in the range of $300 million to $310 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...